

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 February 2004 (19.02.2004)

PCT

(10) International Publication Number
WO 2004/015122 A1

(51) International Patent Classification⁷: **C12P 15/00,**
C07C 49/513

YEANDLE, David, Alan [GB/GB]; GlaxoSmithKline,
Clarendon Road, Worthing, Sussex BN14 8QH (GB).

(21) International Application Number:
PCT/GB2003/003452

(74) Agents: **REEVES, Julie, Frances** et al.; GlaxoSmithK-
line, Corporate Intellectual Property CN925.1, 980 Great
West Road, Brentford, Middlesex TW8 9GS (GB).

(22) International Filing Date: 7 August 2003 (07.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0218578.3 9 August 2002 (09.08.2002) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **GLAXO
GROUP LIMITED** [GB/GB]; Glaxo Wellcome House,
Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **REES, Michael,**
John [GB/GB]; GlaxoSmithKline, New Frontiers Sci-
ence Park South, Third Avenue, Harlow, Essex CM19
5AW (GB). **ROBINS, Keith, Graham** [GB/GB]; c/o
GlaxoSmithKline, 980 Great West Road, Brentford, Mid-
dlesex TW8 9GS (GB). **STEFANSKA, Anna, Louisa**
[GB/GB]; c/o GlaxoSmithKline, 980 Great West Road,
Brentford, Middlesex TW8 9GS (GB). **THIRKETTLE,**
Jan, Edward [GB/GB]; GlaxoSmithKline, Clarendon
Road, Worthing, Sussex BN14 8QH (GB). **VERRALL,**
Michael, Sidney [GB/GB]; c/o GlaxoSmithKline, 980
Great West Road, Brentford, Middlesex TW8 9GS (GB).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: METHOD FOR REPRODUCING PLEUROMUTILINS



(57) Abstract: The present invention provides a method for preparing one or more pleuromutilins comprising the steps of: a) cultur-
ing a pleuromutilins-producing microorganism in a liquid culture medium; and b) extracting the pleuromutilins from the unfiltered
culture medium with a water immiscible organic solvent.

WO 2004/015122 A1

METHOD FOR PRODUCING PLEUROMUTILINS


The present invention relates to a process for the preparation of one or more
 5 pleuromutilins, in particular pleuromutilin.

Pleuromutilin, the compound of formula (1), is a naturally occurring antibiotic
 which has antimycoplasmal activity and modest antibacterial activity. Mutilin and other
 compounds with a free OH at C-14 are inactive. The impact of further modification at C-
 14 on the activity of pleuromutilin has been investigated. It has been shown that the
 10 antimicrobial activity can be improved by replacing the glycolic ester moiety at position
 14 by an R-X-CH₂CO₂- group, where R is an aliphatic or aromatic moiety and X is O, S,
 or NR' (H Egger and H Reinshagen, *J. Antibiotics*, 1976, **29**, 923). Tiamulin, the
 compound of formula (2), which is used as a veterinary antibiotic, is a derivative of this
 type (G Hogenauer in *Antibiotics*, Vol. V, part 1, ed. F E Hahn, Springer-Verlag, 1979,
 15 p.344).



In this application, the non-conventional numbering system which is generally
 used in the literature (G Hogenauer, loc.cit.) is used.

20 More recently, further pleuromutilins have been described having the general
 formula (3).



25 For example, WO 97/25309 (SmithKline Beecham) describes further modification
 of the acyloxy group, disclosing 14-O-carbamoyl derivatives in which the N-atom of the
 carbamoyl group is unsubstituted, mono- or di-substituted.

WO 98/05659 (SmithKline Beecham) discloses 14-*O*-carbamoyl derivatives in which the N-atom of the carbamoyl group is acylated by a group which includes an azabicyclic moiety.

WO 99/21855 (SmithKline Beecham) describes further derivatives in which the glycolic ester moiety at position 14 is replaced by the group
5 $R^2(CH_2)_mX(CH_2)_nCH_2COO^-$ in which R^2 is a non-aromatic mono- or bicyclic group.

WO 00/27790 (SmithKline Beecham) describes C-14 spirocyclic, acylcarbamate, heteroarylalkyl carboxylate or arylalkoxyalkyl carboxylate derivatives.

WO 00/37074 (SmithKline Beecham) describes further derivatives having a
10 heteroaryl acetate substituent at the C-14 position.

WO 00/73287 (SmithKline Beecham) describes further derivatives having an isoxazoline carboxylate substituent at the C-14 position.

WO 01/14310 (SmithKline Beecham) describes further derivatives having a β -ketoester substituent at the C-14 position.

WO 01/74788 (SmithKline Beecham) describes 2-hydroxymutilin carbamate
15 derivatives.

WO 02/12199 (SmithKline Beecham) describes derivatives having a heterocyclic ester substituent at the C-14 position.

WO 02/30929 (SmithKline Beecham) describes derivatives having an
20 oxycarbonyl carbamate substituent at the C-14 position.

WO 02/38528 (SmithKline Beecham) describes derivatives having a malonamide or malonic ester substituent at the C-14 position.

In addition, 19,20-dihydro-2 α -hydroxy-mutilin is described by G. Schulz and H. Berner in *Tetrahedron*, 1984, vol. 40, pp 905-917, and a number of C-14 ether,
25 carbamate, amide and urea derivatives are described by Brooks *et al.* in *Bioorg. Med. Chem.*, 2001, vol. 9, pp1221-1231.

Pleuromutilin may be produced by the fermentation of microorganisms such as *Clitopilus* species, *Octojuga* species and *Gerronema* species. These organisms may also produce a number of related pleuromutilins, for example mutilin 14-acetate. These other
30 pleuromutilins are produced at varying levels depending on the organism and the culture conditions (F Knauseder and E Brandl, Pleuromutilins: Fermentation, Structure and Biosynthesis, *J. Antibiotics*, 1976, 29,125-131), but they are typically less abundant than pleuromutilin.

Following fermentation, pleuromutilin and the other pleuromutilins are present in
35 both the fermentation medium and within the microorganism cells. Known methods for the extraction and subsequent purification of pleuromutilins are disclosed in US patents 4,092,424, 4,129,721, 4,247,542, GB patent 1,197,942 and published in papers such as Antibiotic Substances from Basidiomycetes VIII, F. Kavanagh *et al.*, *Proc. N.A.S.*, 1951, 570-574. The methods include extraction of the filtered broth with a water immiscible
40 solvent e.g. toluene, ethyl acetate or chloroform. Extractions of pleuromutilins from the culture mycelium with a water miscible solvent, for example acetone, followed by extraction with a water immiscible solvent, for example ethyl acetate, are also described. The pleuromutilins are subsequently crystallised from the organic solvent. The

disadvantages of these methods is that they require the separation of the harvested fermentation broth into mycellial pellet and culture liquid for individual extraction.

Accordingly, there is a need to provide an improved method for the extraction of pleuromutilins, in particular pleuromutilin, following fermentation which provides an efficient extraction suited to large scale industrial operations.

The solution to this problem is provided by a process comprising extraction of the whole unfiltered culture medium or fermentation broth, i.e. both fermentation liquid and mycelium, with a water immiscible organic solvent with high specificity for extracting pleuromutilins.

This results in a product of high purity that can be crystallised directly without the need for intermediate purification steps. The benefits and improvements of this process thus include fewer processing steps with high yields as the pleuromutilins present in both the mycelium and the supernatant are recovered.

Thus according to the present invention there is provided a method for preparing one or more pleuromutilins comprising the steps of:

a) culturing a pleuromutilins-producing microorganism in a liquid culture medium; and

b) extracting the pleuromutilins from the unfiltered culture medium with a water immiscible organic solvent.

The resulting pleuromutilins are preferably further purified, for example by crystallization. Thus the present invention also provides a method for preparing one or more pleuromutilins comprising the steps of:

a) culturing a pleuromutilins-producing microorganism in a liquid culture medium;

b) extracting the pleuromutilins from the unfiltered culture medium with a water immiscible organic solvent;

c) concentrating the extracted pleuromutilins; and

d) crystallising the pleuromutilins.

Additionally, the extracted pleuromutilins may be decolourised prior to crystallisation using, for example, activated carbon. Decolorisation may be carried out either after the pleuromutilins have been extracted from the unfiltered culture medium (Step b) or after the extracted pleuromutilins have been concentrated (Step c). Preferably the decolorisation is carried out after the extracted pleuromutilins have been concentrated (Step c).

The pleuromutilins-producing microorganism may be any microorganism capable of producing one or more pleuromutilins. Preferably, the pleuromutilins-producing microorganism used in the process of the present invention is a *Clitopilus* species, for instance *Clitopilus passeckerianus* NRRL 3100/DSM 1602, *Clitopilus passeckerianus* CBS 299.35, *Clitopilus passeckerianus* CBS 330.85, *Clitopilus pinsitus* CBS 623.70 or *Clitopilus hobsonii* CBS 270.36; an *Octojuga* species, for instance *Octojuga pseudopinsitus* NRRL11179; a *Gerronema* species, for instance *Gerronema josserandii* CBS 309.36; or a mutant of any such species. The pleuromutilins-producing microorganism may also be a *Psathyrella* species, for instance *Psathyrella subatrata* CBS 325.39, or a mutant of such species. Particularly preferred is a *Clitopilus* species or a

mutant thereof, especially *Clitopilus passeckerianus* NRRL 3100 or a mutant thereof. Mutants can be prepared by conventional means, for example by UV or chemical mutagenesis.

5 The microorganisms can be grown by fermentation culture techniques well known to those skilled in the art such as those disclosed in US patent 4,092,424.

In the process of the present invention, the water immiscible organic solvent is typically an aromatic hydrocarbon or a water immiscible aliphatic ketone. A preferred aromatic hydrocarbon is toluene and a preferred water immiscible aliphatic ketone is 4-methyl-2-pentanone (MIBK).

10 The extraction can be conducted at about 10°C to about 50°C. Preferably, the extraction is conducted at about 20°C. The pH of the aqueous solution prior to extraction should be in the range 3 to 9. Preferably the pH is near neutrality, e.g. pH 6 to 8, more preferably pH 6.9 ± 0.2 . The pH of the medium may be adjusted by addition of a suitable acid or base, for example acetic acid or sodium hydroxide.

15 In general, ratio ranges of 4:1 to 1:4 equivalent volume of organic solvent to unfiltered culture medium can be used for the extraction. The preferred ratio is 1:2 organic solvent to unfiltered culture medium.

In one embodiment of the present invention, the solvent and unfiltered culture medium may be mixed inline by impinging the two streams and passing through a baffled
20 tube or mechanical mixer. The phases may then be separated by passing through a centrifugal separator such as a disk stack centrifuge or preferably a combined extraction/separation decanter such as a scroll (counter current) decanter.

Alternatively, the extraction may be carried out by stirring the two phases in a tank and allowing the combined phases to settle under gravity or by using a counter current
25 extraction column or similar device which provides intimate contact between the two phases and subsequent separation.

After separation of the organic layer, concentration of the extract by volume reduction of the solvent may be carried out *in vacuo* or by other methods well-known to those skilled in the art. After volume reduction, the pleuromutilins may be crystallised
30 from the concentrated extract. The pleuromutilins can be directly crystallised from toluene or MIBK. Preferably MIBK crystallisations are carried out with the addition of miscible non-polar solvents, for example heptane.

The concentration of the toluene solution used for crystallisation may be from 10% to 50% w/w. The initial temperature of the toluene is preferably from 60°C to 70°C,
35 followed by cooling to from 0°C to 5°C for 8-10 hours to complete crystallisation.

The concentration of the MIBK solution used for crystallisation may be from 20% to 45% w/w, preferably from 35 to 40% w/w. The initial temperature of the MIBK is generally from 45°C to 60°C, especially from 50 to 55°C, cooling to from 25°C to 35°C, especially approximately 30°C, to initiate crystallisation. Up to about 2 volumes of
40 heptane may be added to aid crystallisation. Preferably 1 to 1.5 volumes are added. The heptane may be added over 15 min to 1 hour. After heptane addition, the crystallisation mix is preferably cooled to 0 – 5°C but may be held at ambient temperature.

As discussed above, prior to crystallisation, the pleuromutilins extract or concentrate may optionally be decolourised using activated carbon. For example, the

mutilin concentrate may be batch treated with powdered or granulated charcoal, or passed through a cartridge, column or filter bed packed with charcoal. A ratio of up to 1:15 carbon:pleuromutilins w/w is normally used. The concentration of pleuromutilins in the MIBK for the decolourisation step may be 1-40%, preferably 7-20% w/w. In the case of
5 batch treatment, an activated carbon such as Norit GSK (Norit UK Ltd, Clydesmill Place, G32 8RF, UK) may be used.



The crystallised product prepared according to the process of the present invention may comprise one or more pleuromutilins. Generally, the crystallised product is pleuromutilin which may contain minor related pleuromutilins in addition to
10 pleuromutilin, in particular mutilin 14-acetate. The crystallised product may be used to prepare semi-synthetic pleuromutilins derivatives without further purification. For example, a mixture of pleuromutilin and mutilin 14-acetate can be hydrolysed to mutilin, which may then be used as a synthetic starting material. However, the process of the present invention is preferably used to produce pleuromutilin. Accordingly, the
15 crystallised pleuromutilins product may be further purified by methods such as recrystallisation, for example recrystallisation from ethyl acetate and heptane or from MIBK and heptane.

In one embodiment of the present invention, mutilin 14-acetate may be selectively removed from the pleuromutilins product by recrystallisation from ethyl acetate and
20 heptane. The concentration of pleuromutilins in ethyl acetate for crystallisation may be from 20 to 40% w/w, preferably from 20 to 30% w/w, especially about 30% w/w. The initial temperature for the process is preferably from 45°C to 50°C, cooling to from 15 °C to 25 °C, especially about 20°C, to initiate crystallisation, followed by heptane addition and further cooling to ambient, or preferably 0 to 5°C. 0 to 2 volumes of heptane,
25 preferably 1-1.5 volumes, may be added to aid crystallisation. The heptane is typically added over a period of 15 min to 1 hour, but may be added more slowly.

In a further embodiment of the present invention, mutilin 14-acetate may be selectively removed from the pleuromutilins product by recrystallisation from MIBK and heptane. Where the initial extraction and crystallisation has been carried out using
30 MIBK, use of MIBK in the recrystallisation step has the advantage that recrystallisation can be carried out on either dried product or *in situ* on wet cake (i.e. the pleuromutilins product obtained directly from crystallisation, prior to drying) without generating a complex mixture of solvents. The concentration of the MIBK solution used for recrystallisation may be from 20% to 45% w/w, preferably from 35 to 45% w/w. The
35 initial temperature of the MIBK is generally from 45°C to 65°C, especially about 60°C. Up to about 2 volumes of heptane may be added to aid crystallisation. Preferably 1 to 1.5 volumes are added. The heptane may be added over 10 min to 1 hour, preferably over 10 min to 30 min. After heptane addition, the crystallisation mix is preferably cooled to 0 – 5°C.

40 In one preferred embodiment, the pleuromutilins prepared according to the process of the present invention are used to prepare the semi-synthetic pleuromutilins derivatives described in WO 99/21855, which are incorporated herein by reference. Thus, the pleuromutilins prepared according to the process of the present invention are

preferably used to prepare a semi-synthetic pleuromutilins derivative of general formula (4A) or (4B):



in which:

each of n and m is independently 0, 1 or 2;

10 X is selected from -O-, -S-, -S(O)-, -SO₂-, -CO.O-, -NH-, -CONH-, -NHCONH- and a bond;

R⁷ is vinyl or ethyl;

R⁸ is an optionally substituted non-aromatic monocyclic or bicyclic group containing one or two basic nitrogen atoms and attached through a ring carbon atom;

15 R⁹ is H or OH; or

the moiety R⁸(CH₂)_mX(CH₂)_nCH₂COO at position 14 of (4A) or (4B) is replaced by R^aR^bC=CHCOO in which one of R^a and R^b is hydrogen and the other is R⁸ or R^a and R^b together form R⁸; or

a pharmaceutically acceptable salt thereof.

20 When R⁸ is monocyclic, it typically contains from 4 to 8 ring atoms, and, when bicyclic, it typically contains from 5 to 10 ring atoms in each ring, and is optionally substituted by up to 3 substituents. Suitable substituents include alkyl, alkyloxy, alkenyl and alkenyloxy, each of which may be carried by either a bridgehead or a non-bridgehead carbon atom. In addition, the or each nitrogen atom may be substituted by oxygen, to

25 form an N-oxide, or by mono- or dialkyl, in which case it will be appreciated that a quaternary cation can be formed. The counterion may be a halide ion such as chloride or bromide, preferably chloride. The aza ring system additionally may contain one or more double bonds.

Representative bicyclic and monocyclic groups for R⁸ include piperidinyl,

30 pyrrolidyl, quinuclidinyl, azabicyclo[2.2.1]heptyl, azabicyclo[4.3.0]nonyl,

azabicyclo[3.2.1]octyl, azabicyclo[3,3,0]octyl, azabicyclo[2.2.2]octyl, azabicyclo[3.2.1]octenyl, azabicyclo[3.3.1]nonyl and azabicyclo[4.4.0]decyl, all of which may be substituted or unsubstituted. Preferred examples for R⁸ include quinuclidinyl.

Preferably, n is 0. Preferably, m is 0 or 1.

5 Preferred compounds are those of formula (4A).

Alkyl and alkenyl groups referred to herein with reference to formula (4A) or (4B) include straight and branched groups containing up to six carbon atoms and are optionally substituted by one or more groups selected from the group consisting of aryl, heterocyclyl, (C₁₋₆)alkoxy, (C₁₋₆)alkylthio, aryl(C₁₋₆)alkoxy, aryl(C₁₋₆)alkylthio, amino, mono- or
10 di-(C₁₋₆)alkylamino, cycloalkyl, cycloalkenyl, carboxy and esters thereof, amides of carboxy, ureido, carbamimidoyl (amidino), guanidino, alkyl-sulfonyl, amino-sulfonyl (C₁₋₆)acyloxy, (C₁₋₆)acylamino, azido, hydroxy, and halogen.

Cycloalkyl and cycloalkenyl groups referred to herein with reference to formula (4A) or (4B) include groups having from three to eight ring carbon atoms and are
15 optionally substituted as described hereinabove for alkyl and alkenyl groups.

When used herein with reference to formula (4A) or (4B), the term "aryl" means single and fused rings suitably containing from 4 to 7, preferably 5 or 6, ring atoms in each ring, which rings may each be unsubstituted or substituted by, for example, up to three substituents. A fused ring system may include aliphatic rings and need include only
20 one aromatic ring. Representative aryl groups include phenyl and naphthyl such as 1-naphthyl or 2-naphthyl.


Suitably any aryl group, including phenyl and naphthyl, may be optionally substituted by up to five, preferably up to three substituents. Suitable substituents include halogen, (C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl,
25 halo(C₁₋₆)alkyl, aryl(C₁₋₆)alkoxy, hydroxy, nitro, cyano, azido, amino, mono- and di-*N*-(C₁₋₆)alkylamino, acylamino, arylcarbonylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-*N*-(C₁₋₆)alkylcarbonyl, (C₁₋₆)alkoxycarbonyl, aryloxy carbonyl, ureido, guanidino, sulphonylamino, aminosulphonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkyl sulphinyl, (C₁₋₆)alkylsulphonyl, heterocyclyl and heterocyclyl (C₁₋₆)alkyl.
30 In addition, two adjacent ring carbon atoms may be linked by a (C₃₋₅)alkylene chain, to form a carbocyclic ring.

When used herein with reference to formula (4A) or (4B), the terms "heterocyclyl" and "heterocyclic" suitably include, unless otherwise defined, aromatic and non-aromatic, single and fused, rings suitably containing up to four heteroatoms in each ring, each of
35 which is selected from oxygen, nitrogen and sulphur, which rings, may be unsubstituted or substituted by, for example, up to three substituents. Each heterocyclic ring suitably has from 4 to 7, preferably 5 or 6, ring atoms. A fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring.

Preferably substituents for a heterocyclyl group are selected from halogen, (C₁₋₆)alkyl, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl, halo(C₁₋₆)alkyl,
40 hydroxy, amino, mono- and di-*N*-(C₁₋₆)alkyl-amino, acylamino, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-*N*-(C₁₋₆)alkylcarbonyl, aryloxy carbonyl, (C₁₋₆)alkoxycarbonyl(C₁₋₆)alkyl, aryl, oxy groups, ureido, guanidino, sulphonylamino,

aminosulphonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkylsulphinyl, (C₁₋₆)alkylsulphonyl, heterocyclyl and heterocyclyl(C₁₋₆)alkyl.

In a further preferred embodiment, the pleuromutilins prepared according to the process of the present invention are used to prepare the semi-synthetic pleuromutilins derivatives described in WO 01/74788, which are incorporated herein by reference. Thus, the pleuromutilins prepared according to the process of the present invention are preferably used to prepare a semi-synthetic pleuromutilins derivative of general formula (5):



(5)

in which:

R¹⁰ is a 5- or 6-membered optionally substituted heteroaryl group; and

R¹¹ is vinyl or ethyl;

or a pharmaceutically acceptable salt thereof.

Examples of heteroaryl groups for R¹⁰ include those having a 5 or 6-membered single ring comprising 1 or 2 nitrogen atoms and optionally comprising a further heteroatom selected from oxygen or sulphur, for example pyridine, pyridazine, pyrimidine, pyrazine, isoxazole, thiazole, imidazole, pyrazole; or a 5 or 6-membered ring comprising 3 nitrogen atoms, for example, 1,2,3-triazole, 1,2,4-triazole; or a 5 or 6-membered ring comprising 1 or 2 nitrogen atoms fused to a benzene ring, for example, benzimidazole. Further examples of heteroaryl groups for R¹⁰ include those having a 5 or 6-membered ring comprising 1 or 2 nitrogen atoms fused to a second 5 or 6-membered optionally substituted heteroaryl ring comprising 1 or 2 nitrogen atoms.

Representative examples of such heteroaryl groups for R¹⁰ include, for example, pyridine, pyrazine, pyridazine, 3-oxo-3,4-dihydropyrido[2,3-b]pyrazine, pyrazolo[1,5-a]pyrimidine, pyrimidine, and thiazole. Preferred examples of such heteroaryl groups for R¹⁰ include, for example, pyridine, pyrimidine, and thiazole.

Representative optional substituents for R¹⁰ include amino, mono- or di-(C₁₋₆)alkylamino, (C₁₋₆)alkyl, (C₁₋₆)alkoxy, nitro and N-containing heterocyclyl such as piperidin-4-yl which may be optionally substituted. Typically R¹⁰ may comprise one or two substituents.

When used herein with reference to formula (5), the term "aryl" refers to, unless otherwise defined, phenyl or naphthyl. A substituted aryl group comprises up to five, preferably up to three substituents.

Suitable substituents for an aryl group, including phenyl when forming part of a benzyl group, include, for example, and unless otherwise defined, halogen, (C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, (C₁₋₆)alkoxy, (C₁₋₆)alkoxy(C₁₋₆)alkyl, halo(C₁₋₆)alkyl, aryl(C₁₋₆)alkoxy, hydroxy, nitro, cyano, azido, amino, mono- and di-*N*-
5 (C₁₋₆)alkylamino, acylamino, arylcarbonylamino, acyloxy, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-*N*-(C₁₋₆)alkylcarbamoyl, (C₁₋₆)alkoxycarbonyl, aryloxy, ureido, guanidino, (C₁₋₆)alkylguanidino, amidino, (C₁₋₆)alkylamidino, sulphonylamino, aminosulphonyl, (C₁₋₆)alkylthio, (C₁₋₆)alkylsulphanyl, (C₁₋₆)alkylsulphonyl, heterocyclyl, heteroaryl, heterocyclyl(C₁₋₆)alkyl and
10 heteroaryl(C₁₋₆)alkyl. In addition, two adjacent ring carbon atoms may be linked by a (C₃₋₅)alkylene chain, to form a carbocyclic ring.

When used herein with reference to formula (5), the terms "alkyl" and "alkenyl" refer to (individually or as part of alkoxy or alkenyloxy) straight and branched groups containing up to six carbon atoms.

15 When used herein with reference to formula (5), the terms "cycloalkyl" and "cycloalkenyl" refer to groups having from three to eight ring carbon atoms.

When substituted, an alkyl, alkenyl, cycloalkyl or cycloalkenyl group may comprise up to four substituents, preferably up to two substituents. Suitable substituents for alkyl, alkenyl, cycloalkyl or cycloalkenyl groups include aryl, heteroaryl, heterocyclyl,
20 (C₁₋₆)alkoxy, (C₁₋₆)alkylthio, aryl(C₁₋₆)alkoxy, aryl(C₁₋₆)alkylthio, amino, mono- or di-(C₁₋₆)alkylamino, cycloalkyl, cycloalkenyl, carboxy and esters thereof, amide, ureido, guanidino, (C₁₋₆)alkylguanidino, amidino, (C₁₋₆)alkylamidino, (C₁₋₆)acyloxy, azido, hydroxy, and halogen.

When used herein with reference to formula (5) the terms "heterocyclyl" and
25 "heterocyclic" refer to, unless otherwise defined, non-aromatic, single and fused, rings suitably containing up to four heteroatoms in each ring, each of which is selected from oxygen, nitrogen and sulphur. Each heterocyclic ring preferably has from 4 to 7, preferably 5 or 6, ring atoms. A fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring.

30 When substituted, a heterocyclyl group may comprise up to three substituents. Preferably a substituent for a heterocyclyl group is selected from oxo, and the group hereinbefore defined as suitable aryl substituents.

When used herein with reference to formula (5), the term "heteroaryl" suitably includes, unless otherwise defined, a mono- or bicyclic heteroaromatic ring system
35 comprising up to four, preferably 1 or 2, heteroatoms each selected from oxygen, nitrogen and sulphur. Each ring may have from 4 to 7, preferably 5 or 6, ring atoms. A bicyclic heteroaromatic ring system may include a carbocyclic ring.

When substituted, a heteroaryl group may comprise up to three substituents. Preferably a substituent for a heteroaryl group is selected from the group hereinbefore
40 defined as suitable aryl substituents.

Depending on the position of attachment of substituents, two or more diastereoisomers may be possible. In that situation the present invention includes the individual diastereoisomers and mixtures thereof.

The 2-hydroxy compounds of formula (4A) may be of the (2*S*) configuration or the (2*R*) configuration, or be provided as mixtures thereof. The (2*S*) configuration is preferred. The 2-hydroxy-substituted compounds of formula (5) are of the 2-(*S*) configuration.

5 When used herein, the term "pleuromutilins" includes pleuromutilin (compound of formula (1) as defined above) and pleuromutilin-related compounds such as, for example, pleuromutilin esters such as pleuromutilin 22-acetate or esters of fatty acids, mutilin, or mutilin 14-acetate. In particular, the term "pleuromutilins" includes pleuromutilin and mutilin 14-acetate, especially pleuromutilin.

10 When used herein, the term "pleuromutilins derivative" includes semi-synthetic derivatives prepared from the pleuromutilins produced according to the process of the present invention by, for example, functional group interconversion.

The pleuromutilins produced by the method of the present invention may be analysed by HPLC. Pleuromutilins in broth and extraction samples can be determined using a C18 Waters Spherisorb S5 ODS2 column, 4.6 x 250mm, with a 10mm guard column. UV detection is at 205 nm. An isocratic mobile phase of 1ml/min 45% MeCN in water and a 20 µl injection volume are used. For broth samples, 2ml of whole broth is sonicated for 15 min with 4ml of acetonitrile and filtered through a glass fibre filter paper prior to assay.

20 All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The invention is illustrated by the following Examples.

25

Example 1

Isolation of pleuromutilin using toluene extraction

1,364L of *Clitopilus passeckerianus* NRRL 3100 whole broth at 1,280 mg/L pleuromutilin (1,746g) was adjusted to pH 7 using 20% sodium hydroxide and extracted with a half volume of toluene. The extraction and separation was carried out using a Westfalia SA-7-01 centrifuge and Westfalia TA-7 disc stack centrifuge. Pump flows were adjusted to give 3L/min whole broth and 1.5 L/min toluene. 681L of toluene extract at 2,573 mg/L (1,751g pleuromutilin) was obtained. (100% Stage yield)

35 6.76L of part concentrate toluene extract prepared from the pleuromutilin extract, containing 17.74g/L pleuromutilin (119.9g), was further concentrated to 760ml (15.8% w/v pleuromutilin) (at 60°C, *in vacuo*). The toluene concentrate was allowed to cool to room temperature with stirring and crystallization commenced. The slurry was left at 5°C overnight. Crystals were recovered by filtration on Whatman number 541 paper, washed with 2 x 20 ml cold heptane and dried for 48hr at 55°C, 900mBarg. 89.6g of 100% pure crystalline pleuromutilin were obtained. (75% stage yield)

40

Example 2

Isolation of pleuromutilin using toluene extraction

2,600L of *Clitopilus passereckianus* NRRL 3100 fermentation broth, containing pleuromutilin at 1500ug/g, were extracted with toluene at a broth/solvent ratio of 2:1 using a Westfalia CA226 scroll decanter. The pH was maintained between 6.8-7.5 (1M NaOH), and the extraction carried out at ambient temperature. Passage through a Westfalia TA-7 separator was used to polish the rich solvent stream. 1,275L of rich solvent, containing 2400ug/ml of pleuromutilin were collected. (Solvent extraction yield 76%)

1,275L of pleuromutilin rich toluene were concentrated to 22.5L(16%w/w) using vacuum distillation, 60-75°C and 25in Hg. (Concentration yield 93.5%)

The 22.5L of pleuromutilin concentrate was divided into two approximately equal aliquots and further concentrated on a rotary evaporator (70°C) to between 40-50%w/w (crystallisation observed from approximately 25%w/w). Crystallisation was completed overnight in an ice/water bath.

The product was recovered via filtration through a No.54 Whatman filter paper.

The weighed, wet product (2 x 1.83kg) was slurried in 1L of toluene per kg of wet product for 2 min and the product again recovered via filtration. The dry bed was washed with 0.5kg toluene per kg of original wet product. (Crystallisation yield 86.7%)

2 x 1.5kg wet product dried overnight at 45-50°C, under vacuum to give a total of 2.59kg of pleuromutilin product at 95.7% purity. (Overall yield 61.5%)

Example 3

Isolation of pleuromutilin using MIBK Extraction

1,397L of *Clitopilus passeckerianus* NRRL 3100 whole broth containing 1,280 mg/L pleuromutilin (1,788g) was adjusted to pH 7 using 20% sodium hydroxide. The whole broth was extracted with a half volume of MIBK. The extraction and separation was carried out using a Westfalia SA-7-01 centrifuge and Westfalia TA-7 disc stack centrifuge. Pump flows were adjusted to give 3 L/min whole broth, and 1.5 L/min MIBK. 628L of MIBK extract at 3,010 mg/L was obtained (1,890g pleuromutilin). (100% Stage yield)

2.82L of part concentrated MIBK extract, prepared from the pleuromutilin extract, containing 39.02g/L pleuromutilin (110g) was further concentrated to 0.275L (40% w/v pleuromutilin). The concentrate was cooled to 27°C and crystallization commenced. An equal volume of heptane was added dropwise over 20 min with vigorous agitation. The slurry was held at ambient temperature for 1 hr and then at 5°C overnight. Crystals were recovered by filtration on Whatman number 541 paper washed with 2 x 20 ml cold heptane and dried for 48hr at 55°C, 900mBarg. 98.6g of 96% pure crystalline pleuromutilin were obtained. (86.1% Stage recovery)

Example 4

Isolation of pleuromutilin using MIBK Extraction

A 4500L fermentation of *Clitopilus passeckerianus* NRRL 3100 containing 4.08kg of pleuromutilin was extracted with half volume MIBK. The extraction and separation was carried out using a Westfalia CA226 counter current decanter, and Westfalia TA-7 disc stack centrifuge. Phases were pre-mixed using a Sulzer static mixer.

Maintaining a 2:1 ratio of broth to MIBK, flow rates were increased throughout the process from 3 and 1.5 L/min, to 7 and 3.5 L/min. No degradation of phase separation or extraction efficiency was observed at these flows. MIBK extract was concentrated *in vacuo* to approximately 10% w/v pleuromutilin. 3.62kg of pleuromutilin were recovered to rich extract. (Stage yield 89%)

1L of partially concentrated MIBK extract, from Example 3, containing approximately 100g of pleuromutilin, was further concentrated to 35% w/v pleuromutilin (at 60°C, *in vacuo*). The concentrate was transferred to a 3L flask and stirred at 250rpm. The concentrate was allowed to cool to room temperature and approximately 30mg of seed crystals were added. Crystallization was observed after about 30 min. 1.1 volumes of heptane were then added at 10ml/min, monitoring the stirrer rate to ensure good mixing without excessive splashing. After 1.5 hr at room temperature, the vessel was transferred to a 5°C room for 2 hr. Crystals were recovered on a Whatman 541 paper by vacuum filtration. The crystal cake was washed with 2 x 10 ml of heptane, and dried at 50°C, 900mbar for 48 hr. 84g of 94% pure pleuromutilin crystals were obtained. (Stage yield 79%)

Example 5

Decolourisation of Pleuromutilins from An MIBK Extract Using Activated Carbon

20 Treatment

13kg of MIBK semi-concentrate containing approximately 20%w/w pleuromutilins was treated with 173g Norit GSX powdered carbon [Norit UK Ltd, Clydesmill Place, G32 8RF, UK] and stirred for 5 minutes. The carbon treated concentrate was filtered through a Celite bed [Harborlite UK Ltd, Livingstone Rd, HU13 OEG, UK] to remove the carbon.

Colour based on measurement of Yellowness Index (as defined in standards for measurement of optically clear solutions ASTM D 5386-93b and EN1557), reduced from 32.3 to 18.2 (47% removal).

12kg of the carbon treated rich concentrate was reduced to 6kg using rotary evaporation and transferred to a 30L glass reactor, previously warmed to 50°C using a hot water coil and 8L of warmed MIBK. The MIBK was drained immediately prior to concentrate transfer.

The hot water to the coil was closed and 7L of heptane was added to the concentrate, with agitation, over 25min. The initial temperature during heptane addition was between 55-35°C, followed by natural cooling. On completion of the heptane addition, glycol was introduced to the coil and the temperature reduced to 4°C for crystallisation. The mixture was stirred for 60min.

The crystals were recovered *via* Buchner filtration and the cake washed with 2L of heptane at room temperature. The product was dried overnight on stainless steel trays under vacuum at ambient temperature to yield pale cream free flowing granular crystals (97.7% pleuromutilins). (Stage yield 88.3%)

Example 6

Reduction of Mutilin Impurities by Ethyl Acetate Recrystallisation

12g of crystals of pleuromutilins were dissolved in 100ml of ethyl acetate. The solution was concentrated to 20%w/w and transferred to a 50ml round bottom flask contained in a water bath at 50°C. The water bath temperature was reduced to 20°C and 45ml heptane added with stirring over 30min. The crystals were then stirred in an ice bath for 60min. The recrystallised product was recovered via filtration and the cake washed with 10ml heptane at ambient temperature. The product was dried overnight at ambient temperature under vacuum to yield white, fine, crystals containing 86.2% pleuromutilin and 2.9% mutilin 14-acetate reduction in mutilin 14-acetate was 77.0%. (Stage yield 82.1%)

Example 7

Reduction of Mutilin Impurities by MIBK recrystallisation

30g of Pleuromutilins containing mutilin 14-acetate were dissolved in 80ml MIBK with stirring, in a glass jacketed reaction vessel controlled at 60°C. The vessel was closed to atmosphere during dissolution. When the solid was fully dissolved, 80ml of heptane at ambient temperature was added from a dropping funnel over 15-20min whilst maintaining the temperature of the pleuromutilin solution at 60°C. On completion of the heptane addition the slurry was transferred to a 600ml glass beaker, covered with cling film and stirred in a ice bath for 3hr. The recrystallised product was recovered via vacuum filtration through a No.54 Whatman filter paper and the cake washed *in situ* with 40ml of a 3:1 heptane/MIBK mix. The cake was pulled dry on the filter paper using vacuum before being placed on a tray and dried overnight in a room temperature oven under vacuum with a slight air bleed. This process yielded 22.3g of a white crystalline product containing 1.5 % mutilin 14-acetate w/w (74.5% weight yield, 81.2% yield as pleuromutilin, 84% 14-mutilin acetate removal).

CLAIMS

1. A method for preparing one or more pleuromutilins comprising the steps of:
5 a) culturing a pleuromutilins-producing microorganism in a liquid culture medium; and
b) extracting the pleuromutilins from the unfiltered culture medium with a water immiscible organic solvent.
- 10 2. A method for preparing one or more pleuromutilins comprising the steps of:
a) culturing a pleuromutilins-producing microorganism in a liquid culture medium;
b) extracting pleuromutilins from the unfiltered culture medium with a water immiscible organic solvent;
15 c) concentrating the extracted pleuromutilins; and
d) crystallising the pleuromutilins.
3. A method according to claim 2 wherein the extracted pleuromutilins (Step b) or the concentrated pleuromutilins (Step c) are decolourised using activated carbon.
20
4. A method according to any one of the preceding claims for preparing pleuromutilin.
5. A method according to any one of the preceding claims wherein the
25 pleuromutilins-producing microorganism is a *Clitopilus* species, an *Octojuga* species, a *Gerronema* species, a *Psathyrella* species, or a mutant thereof.
6. A method according to claim 5 wherein the pleuromutilins-producing microorganism is *Clitopilus passeckerianus* NRRL 3100/DSM 1602, *Clitopilus*
30 *passeckerianus* CBS 299.35, *Clitopilus passeckerianus* CBS 330.85, *Clitopilus pinsitus* CBS 623.70, *Clitopilus hobsonii* CBS 270.36, *Octojuga pseudopinsitus* NRRL11179, *Gerronema josserandii* CBS 309.36, *Psathyrella subatrata* CBS 325.39, or a mutant thereof.
- 35 7. A method according to claim 6 wherein the pleuromutilins-producing microorganism is *Clitopilus passeckerianus* NRRL 3100 or a mutant thereof
8. A method according to any one of the preceding claims wherein the water immiscible organic solvent is an aromatic hydrocarbon or a water immiscible aliphatic
40 ketone.
9. A method according to claim 8 wherein the aromatic hydrocarbon is toluene.

10. A method according to claim 8 wherein the water immiscible aliphatic ketone is MIBK.
11. A method according to any one of the preceding claims wherein the extraction is conducted at about 10°C to about 50°C.
12. A method according to any one of the preceding claims wherein the pH of the aqueous solution prior to extraction is in the range pH 6 to 8.
13. A method according to any one of the preceding claims wherein a ratio of 4:1 to 1:4 equivalent volume of organic solvent to unfiltered culture medium is used for the extraction.
14. A method according to any one claims 2 to 13 wherein the pleuromutilins are directly crystallised from toluene or MIBK.
15. A method according to claim 14 wherein the pleuromutilins are directly crystallised from toluene and the concentration of the toluene solution used for crystallisation is from 10% to 50% w/w.
16. A method according to claim 14 or 15 wherein the pleuromutilins are directly crystallised from toluene and the initial temperature of the toluene is from 60°C to 70°C, followed by cooling to from 0°C to 5°C for 8-10 hours.
17. A method according to claim 14 wherein the pleuromutilins are directly crystallised from MIBK and the concentration of the MIBK solution used for crystallisation is from 20% to 45% w/w.
18. A method according to claim 14 or 15 wherein the pleuromutilins are directly crystallised from MIBK and the initial temperature of the MIBK is from 45°C to 60°C, followed by cooling to from 25°C to 35°C.
19. A method according to any one of claims 2 to 13 wherein the pleuromutilins are directly crystallised from MIBK and a miscible non-polar solvent.
20. A method according to claim 19 wherein the miscible non-polar solvent is heptane.
21. A method according to any one of claims 2 to 20 wherein the crystallised pleuromutilins are further purified by recrystallisation.
22. A method according to claim 21 wherein mutilin 14-acetate is selectively removed from the crystallised pleuromutilins by recrystallisation with ethyl acetate and heptane.

23. A method according to claim 21 or claim 22 wherein the concentration of pleuromutilins used for recrystallisation is from 20% to 40% w/w.

24. A method according to any one of claims 21 to 23 wherein the initial temperature is from 45 °C to 50 °C, followed by cooling to from 15 °C to 25 °C.

25. A method according to claim 24 followed by heptane addition and further cooling to 0 °C to 5 °C.



26. A method according to claim 21 wherein mutilin 14-acetate is selectively removed from the crystallised pleuromutilins by recrystallisation with MIBK and heptane.

27. A method according to claim 21 or claim 26 wherein the concentration of pleuromutilins used for recrystallisation is from 20% to 45% w/w.

28. A method according to any one of claims 21, 26 and 27 wherein the initial temperature is from 45 °C to 65 °C.

29. A method of preparing a semi-synthetic pleuromutilins derivative comprising preparation of pleuromutilins by a process claimed in any one of the preceding claims.

30. A method according to claim 29 wherein the semi-synthetic pleuromutilins derivative is a compound of general formula (4A) or (4B):



in which:

each of n and m is independently 0, 1 or 2;

X is selected from -O-, -S-, -S(O)-, -SO₂-, -CO.O-, -NH-, -CONH-, -NHCONH- and a bond;

R⁷ is vinyl or ethyl;

R⁸ is an optionally substituted non-aromatic monocyclic or bicyclic group containing one or two basic nitrogen atoms and attached through a ring carbon atom;

R⁹ is H or OH; or


the moiety R⁸(CH₂)_mX(CH₂)_nCH₂COO at position 14 of (4A) or (4B) is replaced by R^aR^bC=CHCOO in which one of R^a and R^b is hydrogen and the other is R⁸ or R^a and R^b together form R⁸; or

a pharmaceutically acceptable salt thereof.

31. A method according to claim 30 wherein the semi-synthetic pleuromutilins derivative is a compound of formula (4A) or (4B) wherein R⁸ is selected from optionally substituted piperidinyl, pyrrolidyl, quinuclidinyl, azabicyclo[2.2.1]heptyl, azabicyclo[4.3.0]nonyl, azabicyclo[3.2.1]octyl, azabicyclo[3.3.0]octyl, azabicyclo[2.2.2]octyl, azabicyclo[3.2.1]octenyl, azabicyclo[3.3.1]nonyl and azabicyclo[4.4.0]decyl.

32. A method according to claim 30 or 31 wherein the semi-synthetic pleuromutilins derivative is a compound of formula (4A) or (4B) wherein R⁸ is substituted by alkyl, alkyloxy, alkenyl or alkenyloxy, which are optionally further substituted by one or more groups selected from aryl, heterocyclyl, (C₁₋₆)alkoxy, (C₁₋₆)alkylthio, aryl(C₁₋₆)alkoxy, aryl(C₁₋₆)alkylthio, amino, mono- or di-(C₁₋₆)alkylamino, cycloalkyl, cycloalkenyl, carboxy and esters thereof, amides of carboxy, ureido, carbamimidoyl (amidino), guanidino, alkyl-sulfonyl, amino-sulfonyl (C₁₋₆)acyloxy, (C₁₋₆)acylamino, azido, hydroxy, and halogen.

33. A method according to claim 29 wherein the semi-synthetic pleuromutilins derivative is a compound of general formula (5):



(5)

in which:

R¹⁰ is a 5- or 6-membered optionally substituted heteroaryl group; and
R¹¹ is vinyl or ethyl;

or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

PCT/GB 03/03452

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12P15/00 C07C49/513

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12P C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PALMA N ET AL: "PLEUROMUTILIN RELATED METABOLITES PRODUCED BY SUBMERGED CULTURE OF THE BASIDIOMYCETOUS GENUS CLITOPILUS KUMMER" PROCEEDINGS OF EUROPEAN CONGRESS BIOTECHNOLOGY, XX, XX, vol. 1, 1984, pages 533-542, XP002047840	1,2,4-7, 11,12
Y	page 533 - page 535	3,21, 29-33
Y	KAVANAGH, FREDERICK ET AL.: PROC. NAT. ACAD. SCI. USA, vol. 37, 1951, pages 570-574, XP0001091347 cited in the application page 570, paragraph 5 - page 571 ----- -/-	3,21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

18 December 2003

Date of mailing of the international search report

07/01/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5815 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Krische, D

INTERNATIONAL SEARCH REPORT

PCT/GB 03/03452

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99/21855 A (SMITHKLINE BEECHAM) 6 May 1999 (1999-05-06) cited in the application claims 1,5 -----	29-32
Y	WO 01/074788 A (SMITHKLINE BEECHAM PLC (GB)) 11 October 2001 (2001-10-11) cited in the application claims 1,10 -----	29,33
Y	US 4 247 542 A (MICHEL KARL H ET AL) 27 January 1981 (1981-01-27) cited in the application claims 1,2; example 4 column 5, line 1 - column 6, line 58 -----	1,2,4-6, 8-10,13, 14
Y	CH 650 531 A (RICHTER GEDEON VEGYESZET) 31 July 1985 (1985-07-31) column 1, line 46 - column 4, line 14 -----	1,2,4-6, 8-10,13, 14

INTERNATIONAL SEARCH REPORT

PCT/GB 03/03452

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9921855	A	06-05-1999	AU 742167 B2	20-12-2001
			AU 9636198 A	17-05-1999
			BR 9814747 A	20-11-2001
			CA 2307551 A1	06-05-1999
			CN 1283197 T	07-02-2001
			EP 1028961 A1	23-08-2000
			WO 9921855 A1	06-05-1999
			HU 0004040 A2	28-05-2001
			JP 2001521033 T	06-11-2001
			NO 20002173 A	05-06-2000
			NZ 504203 A	26-11-2002
			PL 340254 A1	29-01-2001
			TR 200001203 T2	21-08-2000
			US 6281226 B1	28-08-2001
			ZA 9809767 A	28-04-2000
WO 0174788	A	11-10-2001	AU 6382701 A	15-10-2001
			BR 0109809 A	21-01-2003
			CA 2405132 A1	11-10-2001
			CN 1427827 T	02-07-2003
			CZ 20023290 A3	12-03-2003
			WO 0174788 A1	11-10-2001
			EP 1268443 A1	02-01-2003
			HU 0300370 A2	28-06-2003
			JP 2003529593 T	07-10-2003
			NO 20024745 A	19-11-2002
			US 2003114674 A1	19-06-2003
US 4247542	A	27-01-1981	NONE	
CH 650531	A	31-07-1985	HU 183266 B	28-04-1984
			BE 891421 A1	10-06-1982
			CH 650531 A5	31-07-1985
			CS 250211 B2	16-04-1987
			FR 2496123 A1	18-06-1982
			IT 1142098 B	08-10-1986
			JP 1041314 B	05-09-1989
			JP 1556624 C	23-04-1990
			JP 57150398 A	17-09-1982